Clinical Readiness - Practical and Innovative Solutions for AAV Development and Manufacturing
Summary: What are the current challenges and future promises of adeno-associated virus (AAV), lentivirus, and lipid nanoparticles in gene therapies? George Buchman, Ph.D., Vice President of Preclinical & Process Development at Catalent Gene Therapy, discusses specific case studies for neuromuscular degenerative indications, AAV technology and manufacturing, strategies for navigating the current regulatory environments in the U.S. and Europe, and much more in this on-demand webinar.